RxDoctor Payments Data

Sarah Peak, APRN

Nurse Practitioner · Casper, WYNPI 1457054280

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Novo Nordisk at 26.8% of the total. 2025 is the largest year on record at $315, 9.9 times the $32 reported in 2023.

$507in general payments, 2019–2025

Across 26 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$136
  • AstraZeneca$82
  • GSK$64
  • Lundbeck LLC$61
  • Lilly USA, LLC$45
  • Novartis$39
  • plus $81 from 3 others

What the payments were for

  • Food & beverage$507100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$507 in reported general payments places this provider in the 85th percentile of 150 nurse practitioner providers in Wyoming.

See all nurse practitioner providers in Wyoming

Medicare billing

Part B allowed, 2024
$48,308
Medicare patients
247
Services billed
490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$34,707
MounjaroTirzepatide25$25,216
Breo ElliptaFluticasone/Vilanterol25$12,119
FarxigaDapagliflozin Propanediol12$8,320
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,362
EliquisApixaban11$6,269
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen79$2,225
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,725
SynthroidLevothyroxine Sodium18$1,288
Pantoprazole Sodium60$961
Levothyroxine Sodium76$868
Azithromycin44$708
Duloxetine Hcl29$701
Estradiol12$698
Albuterol Sulfate HfaAlbuterol Sulfate31$675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$136$34,70737 claims
Lilly USA, LLCMounjaro$45$25,21625 claims
GSKBreo Ellipta, Trelegy Ellipta$64$19,48036 claims
AstraZenecaFarxiga$82$8,32012 claims
AbbVieSynthroid$37$1,28818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 150 nurse practitioner providers in Wyoming.

Other nurse practitioner in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →